Karyopharm Therapeutics Inc (NASDAQ:KPTI) a clinical-stage pharmaceutical company, today reported that its SINE™ nuclear transport compounds are being evaluated for the treatment of …
In a research report issued today, J.P.
In a research report released today, MLV analyst Arlinda Lee maintained a Buy rating on shares of Karyopharm Therapeutics Inc (NASDAQ:KPTI), and reduced the …
Karyopharm Therapeutics Inc (NASDAQ:KPTI) is catalyst rich over the next 18-months and is at onset of a multi-year re-rate higher. We contend that …
